Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
7,02 AUD | -1,13% | +5,41% | +14,15% |
Omzet 2024 * | 384 mln. 251 mln. 234 mln. | Omzet 2025 * | 429 mln. 280 mln. 261 mln. | Marktkapitalisatie | 576 mln. 376 mln. 350 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -83 mln. -54,15 mln. -50,47 mln. | Nettowinst (verlies) 2025 * | -2 mln. -1,3 mln. -1,22 mln. | EV/omzet 2024 * | 1,31 x |
Nettoliquiditeiten 2024 * | 72,1 mln. 47,03 mln. 43,84 mln. | Nettoliquiditeiten 2025 * | 60,91 mln. 39,74 mln. 37,04 mln. | EV/omzet 2025 * | 1,2 x |
K/w-verhouding 2024 * |
-6,94
x | K/w-verhouding 2025 * |
-207
x | Werknemers | 967 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 70,67% |
Recentste transcriptie over Mayne Pharma Group Limited
1 dag | -1,13% | ||
1 week | +5,41% | ||
Lopende maand | -3,04% | ||
1 maand | +2,48% | ||
3 maanden | +31,71% | ||
6 maanden | +83,29% | ||
Lopend jaar | +14,15% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 01-10-22 |
Aaron Gray
DFI | Director of Finance/CFO | - | 29-08-22 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 30-05-18 |
Patrick Blake
BRD | Director/Board Member | 59 | 28-06-18 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 01-10-22 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 7,02 | -1,13% | 2 107 |
24-04-24 | 7,1 | -0,28% | 73 461 |
23-04-24 | 7,12 | +4,25% | 197 322 |
22-04-24 | 6,83 | +2,55% | 246 992 |
19-04-24 | 6,66 | -1,33% | 130 562 |
uitgestelde koers Australian S.E., 26 april 2024 om 02:27 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+14,15% | 374 mln. | |
+18,51% | 22,25 mld. | |
+13,49% | 14,39 mld. | |
+12,83% | 13,55 mld. | |
+38,02% | 11,27 mld. | |
-10,31% | 6,95 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+6,35% | 5,01 mld. | |
-5,36% | 4,51 mld. |